Skip to search formSkip to main contentSkip to account menu

NBI-3001

Known as: NBI3001 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

interleukin-4-Pseudomonas exotoxin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Distinct cellular responses induced by saporin and a transferrin–saporin conjugate in two different human glioblastoma cell lines
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults, with a median survival of ∼12–18 months post… 
Review
2006
Review
2006
Clinical studies with targeted toxins in malignant glioma.
Targeted toxins represent a new class of agents with high specificity for tumor cells. Toxins in current clinical use for the… 
2005
2005
Phase I Trial of Intravenous IL-4 Pseudomonas Exotoxin Protein (NBI-3001) in Patients with Advanced Solid Tumors That Express the IL-4 Receptor
NBI-3001 is a novel immunotoxin of attenuated Pseudomonas exotoxin fused to circularly permutated IL-4, which has shown some… 
Highly Cited
2004
Highly Cited
2004
Long Term Survival in a Patient with Recurrent Malignantc Glioma Treated with Intratumoral Infusion of an IL4-Targeted Toxin (NBI-3001)
Intratumoral infusion of a recombinant targeted toxin (NBI-3001) consisting of the receptor binding domain of human interleukin 4… 
2004
2004
Safety, Tolerability, and Tumor Response of IL4-Pseudomonas Exotoxin (NBI-3001) in Patients with Recurrent Malignant Glioma
AbstractPurpose: This was an open-label, dose-escalation trial of intratumoral administration of IL-4 Pseudomonas exotoxin (NBI… 
Highly Cited
2003
Highly Cited
2003
Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma
SummaryPurpose: This was an open-label, dose-escalation trial of intratumoral administration of IL-4Pseudomonas exotoxin (NBI… 
Highly Cited
2003
Highly Cited
2003
Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma.
PURPOSE This was an open-label, dose-escalation trial of intratumoral administration of IL-4 Pseudomonas Exotoxin (NBI-3001) in… 
2001
2001
763 Safety, Tolerability and Tumor Response of IL4-toxin (NBI-3001) in Patients with Recurrent Malignant Glioma
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)